1.Long-term Results of Endoscopic Histoacryl(R) (N-butyl-2-cyanoacrylate) Injection for Treatment of Gastric Varices : A 10-year Experience.
Hyun Soo JOO ; Jae Young JANG ; Soo Hoon EUN ; Sang Kyun KIM ; In Seop JUNG ; Chang Beom RYU ; Young Seok KIM ; Jin Oh KIM ; Joo Young CHO ; Yun Soo KIM ; Joon Seong LEE ; Moon Sung LEE ; Chan Sup SHIM ; Boo Sung KIM
The Korean Journal of Gastroenterology 2007;49(5):320-326
BACKGROUND/AIMS: Gastric variceal bleeding is an infrequent but serious complication of portal hypertension. Endoscopic injection of Histoacryl(R) (N-butyl-2-cyanoacrylate) has been approved as an effective treatment for gastric variceal bleeding. The aim of this study was to evaluate the long-term efficacy and safety of the endoscopic injection of Histoacryl(R) for the treatment of gastric varices. METHODS: Between January 1994 and January 2005, eighty-five patients with gastric varices received endoscopic injections of Histoacryl(R) . Among these 85 patients, 65 received the procedure within 1 week after gastric variceal bleeding, and 13 received as a prophylactic procedure. According to the Sarin classification, 32 patients were GOV1 and 53 were GOV2. Most of the varices were large (F2 or F3, 75 patients). The average volume of Histoacryl(R) per each session was 1.43 ml. Among 85 patients, 72 patients were followed-up and the median duration was 24.5 months. RESULTS: The rate of initial hemostasis was 98.6% and recurrent bleeding occurred in 29.2% (21 of 72). When rebleeding occurred, 76.2% was within 1 year after the initial injection. Treatment failure-related mortality rate was 1.4% (1 of 85). Twenty-seven patients died, mostly due to hepatocelluar carcinoma or liver failure. Two patients experienced pulmonary embolism and one experienced splenic infarction. They recovered without specific treatment. Rebleeding rate had a tendency to increase in patients with hepatocelluar carcinoma (p=0.051) and GOV2 (p=0.061). CONCLUSIONS: Histoacryl(R) injection therapy is a effective treatment method for gastric varices with high initial hemostasis rate and low major complications.
Adult
;
Aged
;
Enbucrilate/administration & dosage/*analogs & derivatives/chemistry/therapeutic
;
Endoscopy, Gastrointestinal
;
Esophageal and Gastric Varices/mortality/surgery/*therapy
;
Female
;
Gastrointestinal Hemorrhage/mortality/surgery/*therapy
;
Humans
;
Injections
;
Male
;
Middle Aged
;
Predictive Value of Tests
;
Retrospective Studies
;
Sclerosing Solutions/administration & dosage/*therapeutic use
;
Severity of Illness Index
;
Survival Rate
2.The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding.
Dongmo JE ; Yong Han PAIK ; Geum Youn GWAK ; Moon Seok CHOI ; Joon Hyeok LEE ; Kwang Cheol KOH ; Seung Woon PAIK ; Byung Chul YOO
Clinical and Molecular Hepatology 2014;20(3):283-290
BACKGROUND/AIMS: To investigate the efficacy and longterm outcome of esophageal variceal ligation (EVL) plus propranolol in comparison with propranolol alone for the primary prophylaxis of esophageal variceal bleeding. METHODS: A total of 504 patients were retrospectively enrolled in this study. 330 patients were in propranolol group (Gr1) and 174 patients were in EVL plus propranolol group (Gr2). The endpoints of this study were esophageal variceal bleeding and mortality. Association analyses were performed to evaluate bleeding and mortality between Gr1 and Gr2. RESULTS: EVL was more applied in patients with high risk, such as large-sized varices (F2 or F3) or positive red color signs. Total 38 patients had bleeds, 32 in Gr1 and 6 in Gr2. The cumulative probability of bleeding at 120 months was 13% in Gr1 versus 4% in Gr2 (P=0.04). The predictive factors of variceal bleeding were red color signs (OR 2.962, P=0.007) and the method of propranolol plus EVL (OR 0.160, P=0.000). 20 patients died in Gr1 and 12 in Gr2. Mortality rates are similar in the two groups compared, 6.7% in Gr1 and 6.9% in Gr2. The cumulative probability of mortality at 120 months was not significantly different in the two groups (7% in Gr1, 12% in Gr2, P=0.798). The prognostic factors for mortality were age over 50 (OR 5.496, P=0.002), Child-Pugh class B (OR 3.979, P=0.001), and Child-Pugh class C (OR 10.861, P=0.000). CONCLUSIONS: EVL plus propranolol is more effective than propranolol alone in the prevention of the first variceal bleeding in patients with liver cirrhosis.
Adrenergic beta-Antagonists/*therapeutic use
;
Adult
;
Aged
;
Esophageal and Gastric Varices/*pathology
;
Female
;
Follow-Up Studies
;
Gastrointestinal Hemorrhage/*drug therapy/mortality/surgery
;
Humans
;
Ligation
;
Liver Cirrhosis/etiology
;
Logistic Models
;
Male
;
Middle Aged
;
Odds Ratio
;
Proportional Hazards Models
;
Propranolol/*therapeutic use
;
Retrospective Studies
;
Severity of Illness Index
;
Survival Rate